HIV InfectionsPhase 2NCT00643643
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
A Phase 2 study testing Maraviroc (UK-427,857) in people with HIV Infections, run by ViiV Healthcare at 6 sites in 3 countries.
Trial summary
To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV). Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- HIV Infections
- What is being tested?
- Maraviroc (UK-427,857)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 41 participants
- Where
- 6 sitesin 3 countries
- Study dates
- Oct 2002to Jun 2003
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male with HIV or surgically sterilized female with HIV showing no symptoms of HIV
- Weight between 50 and 90kg and within the permitted range for their height
Who cannot join
- Subjects with a CD4 count less than 250cells/mm3 or HIV viral load of less than 5000 copies/mL
- Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis
- Subjects whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion
- Subjects who have taken anti-retroviral drugs in the eight weeks prior to the study screening visit
Trial locations and contacts
6 sites in 3 countries.
6 sites in 3 countries
Germany3 sites
Pfizer Investigational Site
Bonn, 53105
Pfizer Investigational Site
Cologne, 50924
Pfizer Investigational Site
München, 80336
United Kingdom2 sites
Pfizer Investigational Site
London, NW3 2QG
Pfizer Investigational Site
London, SW10 9NH
About this study
Official title: A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.
To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).
- Conditions
- HIV Infections
- Being tested
- Maraviroc (UK-427,857), Placebo
- Keywords
- HIV, Treatment Naïve
- Medical subject headings
- HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Maraviroc (UK-427,857)Drug
Also called Celsentri, Selzentry
25 mg oral tablet once daily for 10 days
Maraviroc (UK-427,857)Drug
Also called Celsentri, Selzentry
50 mg oral tablet twice daily for 10 days
Maraviroc (UK-427,857)Drug
Also called Celsentri, Selzentry
100 mg oral tablet twice daily for 10 days
Maraviroc (UK-427,857)Drug
Also called Celsentri, Selzentry
300 mg oral tablet twice daily for 10 days
PlaceboOther
Also called Celsentri, Selzentry
Matching placebo oral tablet twice daily for 10 days
| Study group | Role | What they receive |
|---|---|---|
| A | Experimental | Not described Receives: Drug: Maraviroc (UK-427,857) |
| B | Experimental | Not described Receives: Drug: Maraviroc (UK-427,857) |
| C | Experimental | Not described Receives: Drug: Maraviroc (UK-427,857) |
| D | Experimental | Not described Receives: Drug: Maraviroc (UK-427,857) |
| E | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in viral load
Measured: Day 11
Pharmacokinetic profile of UK-427,857
Measured: Days 1 and 10
Receptor saturation
Measured: Days 1, 5, 10, 11, 13, 15, 19, 40
Secondary outcomes (10)
12-lead electrocardiography
Measured: Days 1-11 and Day 40
Time course of viral load from baseline to follow-up
Measured: Days 1-15 and Days 19, 22, 25, 40
Time to rebound of viral load
Measured: Days 1-15 and Days 19, 22, 25, 40
The relationship of change in viral load (from baseline to day 11) versus average (Days 1-11) and trough (Day 10) plasma concentrations
Measured: Days 1-11
The relationship of change in viral load (from baseline to day 11) versus mean receptor saturation (Day 10)
Measured: Days 1-11
The relationship of change from baseline in viral load versus baseline virus susceptibility (IC 50 and IC 90)
Measured: Days 1-11
Adverse events
Measured: Days 1-40
Laboratory safety testing
Measured: Days 1, 3, 7, 11, 15, 40
Physical examination
Measured: Days 1, 11, 40
Supine and standing blood pressure and pulse rate
Measured: Days 1-11 and Day 40
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2008 (estimated)
- Study startOct 2002
- Primary completionJun 2003
- Study completionJun 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- More trials run by ViiV HealthcareThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- ViiV Healthcare
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Pfizer
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00643643
- Sponsor's protocol ID
- A4001007
- Status last verified
- Nov 2010
- First submitted
- 19 Mar 2008
- Last updated
- 10 Nov 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.
- ClinicalTrials.gov ID
- NCT00643643
- Acronym / sponsor ID
- A4001007
- Conditions
- HIV Infections
- Keywords
- HIV, Treatment Naïve
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- ViiV HealthcareIndustry (pharma, biotech, devices)
- Collaborators
- Pfizer
- Study start
- Oct 2002
- Primary completion
- Jun 2003 (actual)
- Study completion
- Jun 2003 (actual)
- First posted
- 26 Mar 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| A | Experimental | Drug: Maraviroc (UK-427,857) |
| B | Experimental | Drug: Maraviroc (UK-427,857) |
| C | Experimental | Drug: Maraviroc (UK-427,857) |
| D | Experimental | Drug: Maraviroc (UK-427,857) |
| E | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Male with HIV or surgically sterilized female with HIV showing no symptoms of HIV
- Weight between 50 and 90kg and within the permitted range for their height
Key exclusion criteria (4 listed)
- Subjects with a CD4 count less than 250cells/mm3 or HIV viral load of less than 5000 copies/mL
- Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis
- Subjects whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion
- Subjects who have taken anti-retroviral drugs in the eight weeks prior to the study screening visit
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Maraviroc (UK-427,857)Also: Celsentri, Selzentry25 mg oral tablet once daily for 10 days | Drug | A |
| Maraviroc (UK-427,857)Also: Celsentri, Selzentry50 mg oral tablet twice daily for 10 days | Drug | B |
| Maraviroc (UK-427,857)Also: Celsentri, Selzentry100 mg oral tablet twice daily for 10 days | Drug | C |
| Maraviroc (UK-427,857)Also: Celsentri, Selzentry300 mg oral tablet twice daily for 10 days | Drug | D |
| PlaceboAlso: Celsentri, SelzentryMatching placebo oral tablet twice daily for 10 days | Other | E |
Primary outcome
Change from baseline in viral load
Time frame: Day 11
Pharmacokinetic profile of UK-427,857
Time frame: Days 1 and 10
Receptor saturation
Time frame: Days 1, 5, 10, 11, 13, 15, 19, 40
10 secondary outcomes
12-lead electrocardiography
Time frame: Days 1-11 and Day 40
Time course of viral load from baseline to follow-up
Time frame: Days 1-15 and Days 19, 22, 25, 40
Time to rebound of viral load
Time frame: Days 1-15 and Days 19, 22, 25, 40
The relationship of change in viral load (from baseline to day 11) versus average (Days 1-11) and trough (Day 10) plasma concentrations
Time frame: Days 1-11
The relationship of change in viral load (from baseline to day 11) versus mean receptor saturation (Day 10)
Time frame: Days 1-11
The relationship of change from baseline in viral load versus baseline virus susceptibility (IC 50 and IC 90)
Time frame: Days 1-11
Adverse events
Time frame: Days 1-40
Laboratory safety testing
Time frame: Days 1, 3, 7, 11, 15, 40
Physical examination
Time frame: Days 1, 11, 40
Supine and standing blood pressure and pulse rate
Time frame: Days 1-11 and Day 40
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2010.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for HIV Infections
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
6 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Maraviroc (UK-427,857) in people with HIV Infections, run by ViiV Healthcare at 6 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Nov 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Germany, United Kingdom, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in viral load (time frame: Day 11). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2010.